2025-03-03 15:18:00
Lund-based Alligator Bioscience continue to strengthen the case for their phase II candidate mitazalimab with 24-months data. BioStock reached out to CEO Søren Bregenholt to get his comments on the updated data.
- These results align well with our expectations and further reinforce our confidence in mitazalimab's potential, says Bregenholt.
Read the full article at biostock.se:
Alligator's CEO: "We are not surprised by the positive readout"
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se